Study on Electroacupuncture's Impact on Bowel Motility in Healthy Subjects
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
Phase III
Gastroenterology / Acupuncture
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
Why it matters
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
What changed
Trial Update
Analysis
A clinical trial is investigating the effects of electroacupuncture at NP82 and SP15 on bowel motility in healthy subjects.
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
Results from the trial regarding changes in bowel motility and any subsequent interest from pharmaceutical companies in acupuncture-based therapies.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.